undamentalytics Newsletter

Leonabio, Inc. insider trading

Every open-market purchase and sale by Leonabio, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
Leonabio, Inc. insider open-market trades
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Leonabio, Inc.’s insiders pay?

From January 27, 2021 to October 28, 2026, 11 insiders reported 14 open-market purchases and 7 sales not made under a pre-set plan in Leonabio, Inc. Twelve months after each purchase was reported, the shares were −71.1% against the S&P 500 on average (median −71.1%), over 2 purchases with a full year of prices; 0% beat the index. That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on January 28, 2021 into $1,017 by November 2, 2026, −32.8% a year. It held shares 35% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $12,743 (+4.3% a year), and held throughout $21,628 (+14.4%).

$0$10.0k$20.0k 202120222023202420252026 $21.6k$12.7k$1.0k
Copying Leonabio, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Leonabio, Inc.'s insiders from January 28, 2021, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 35% of the time.
Leonabio, Inc.: each insider's record
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Litton Mark James PRESIDENT and CEO 0 — — 5 — March 5, 2026
Edelman Joseph Director 3 −69.0% (1) 0% 0 — December 29, 2023
Romano Kelly A Director 3 −73.2% (1) 0% 0 — June 25, 2024
Gengos Andrew See Below 2 — — 0 — June 9, 2023
Moebius Hans Chief Medical Officer 2 — — 0 — November 17, 2022
Johnson James A Director 1 — — 0 — March 30, 2023
Lenington Rachel Chief Operating Officer 0 — — 1 — June 24, 2022
Mileson Glenna Chief Financial Officer 1 — — 0 — December 30, 2022
Pickering Grant Director 1 — — 0 — March 31, 2023
Portman David J. 10% owner 1 — — 0 — October 28, 2026
San Martin Javier CHIEF MEDICAL OFFICER 0 — — 1 — January 5, 2026

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

← Back to Leonabio, Inc. · Funds · Politicians